Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases
Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases
03/02/20, 4:51 PM
Location
san diegoMoney raised
$7 million
Round Type
seed
Primmune Therapeutics today announced that it has raised $7 million in seed financing to support the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonists for long-term systemic activation of innate immunity. Investors in the seed financing were CAM Capital, Charlie McDermott, BioBrit, and BioRock Ventures.
Company Info
Location
san diego, california, united states
Additional Info
Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases. For more information, please visit: www.primmunerx.com.